Benufutamab - Genmab
Alternative Names: GEN1029; HexaBody-DR5/DR5; Hx-DR5-01; Hx-DR5-01/05; Hx-DR5-05; iDD 004Latest Information Update: 28 Jan 2022
At a glance
- Originator iDD Biotech
- Developer Genmab; VU University Medical Center
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- No development reported Multiple myeloma
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Multiple-myeloma in Netherlands
- 12 Oct 2021 Genmab terminates phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease) in USA, United Kingdom, Spain and France (IV) (NCT03576131) (EudraCT2017-001394-16)
- 26 Oct 2019 Pharmacodynamics data from preclinical studies in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019